Difference between revisions of "MSK Biomarker Ctte"
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
'''Approved call summaries:''' | '''Approved call summaries:''' | ||
| + | *[[Media:2018_01-16_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|January 16, 2018]] | ||
*[[Media:2017_11-21_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|November 21, 2017]] | *[[Media:2017_11-21_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|November 21, 2017]] | ||
*[[Media:2017_10-17_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|October 17, 2017]] | *[[Media:2017_10-17_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|October 17, 2017]] | ||
Revision as of 16:41, 21 February 2018
- Co-chairs: Thomas M. Link, MD, PhD; Xiaojuan Li, PhD
- Secretary: Susan Weinmann
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive